Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: Detection of the rare allele CYP2C19*4

Clinical Chemistry

Volumn 45, Issue 12, 1999, Pages 2273-2274

  Garcia Barceló, Mercè ^a   Chow, Lok Yee ^a   Chiu, Helen Fung Kum ^a   Wing, Yun Kowk ^a   Lee, Dominic Tak Shing ^a   Lam, Kwok Lim ^a   Waye, Mary Miu Yee ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450; PHENYTOIN;

ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG METABOLISM; ETHNIC GROUP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PHENOTYPE;

EID: 0032737338     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.12.2273     Document Type: Article

References (14)

1. 1. Lin KM, Anderson D, Poland RE. Ethnicity and psychopharmacology: bridging the gap. Psychiatr Clin N Am 1995:18:635-47.
2. 2. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994:33:1743-52.
3. 3. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995:5:312-7.
4. 4. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994:269:15419-22.
5. 5. de Morais SMF, Goldstein JA, Xie H-G, Huang S-L, Lu Y-Q, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995:58:404-12.
6. 6. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of Smephenytoin metabolism in Japanese. Mol Pharmacol 1994:46:594-8.
7. 7. Xiao Z-A, Goldstein JA, Xie H-G, Blaisdell J, Wang W, Jiang C-H, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997:281:604-9.
8. 8. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM, Price Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian, and American Black populations. Pharmacogenetics 1997; 7:59-64.
9. 9. Ferguson JF, de Morais SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998:284:356-61.
10. 10. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998:286:1490-5.
11. 11. Ibeanu GC, Blaisdell J, Ghanayem Bl, Beyeler C, Benhamou S, Bouchardy C, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998:8:129-35.
12. 12. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and Smephenytoin. Clin Pharmacol Ther 1992:51:388-97.
13. 13. Nowak MP, Sellers EM, Tyndale RF. Canadian native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin Pharmacol Ther 1998:64:378-83.
14. 14. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996:6:193-201.